We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Emerging Markets Encouraged to Focus on Most Likely Counterfeits
Emerging Markets Encouraged to Focus on Most Likely Counterfeits
June 7, 2012
Drugmakers breaking into emerging markets could see supply chain benefits and quicker product launches if these markets automatically registered U.S. Food and Drug Administration (FDA)-approved products before testing for quality issues, according to a new study.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor